


<p><b>Identity:</b>  Title: Prof. Dr.  Family Name(s): Van der Meer  First Name(s): Peter  Age: 46</p>	<p><b>Photo:</b></p> 
<p><b>Application for the following position in the HFA Board or Nominating Committee:</b>  Ordinary Board member</p>	

<p><b>Place of work</b>  <i>If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.</i></p>	
Institute/organisation:	University Medical Center Groningen
Department:	Cardiology
Address:	Hanzeplein 1
Post code / Zip:	9700 RB GRONINGEN
Country:	The Netherlands

**General Curriculum Vitae (500 words max)**  
*Please also include your H index and top 5 to 10 publications in the last 5 years*

- Prof. dr. Peter van der Meer received both his MD and PhD cum laude from the University of Groningen in the Netherlands.
- He did a post-doctoral fellowship at Harvard where he identified new cardiac progenitor cells and established a platform for cell delivery in cardiac regenerative medicine for which he holds a patent. The results of this work were published in Science, awarded by the AHA as one of the top 10 papers in 2009, and for which he received an ACC Young Investigator Award.
- After returning to the Netherlands he became staff cardiologist at the University Medical Center Groningen and initiated his own research group. Ever since, 30 PhD students have finished their theses under his supervision and many of them became cardiologists and/or (assistant) professors to start their own research groups.
- He received numerous grants, including the prestigious European Research Council (ERC) Starting Grant (€1.5Mio) and ERC consolidator Grant (€2Mio)
- His research group consists of PhD students, post-docs and technicians from many nationalities with various backgrounds (biologists, medical doctors, and biomedical-engineers) working on translational topics to bridge the gap between bench and bedside. His group focuses on understanding the susceptibility to develop heart failure and exploring novel treatment targets and therapies.
- He has authored >300 publications and his **H-factor is 89**.
- He is a member of several steering committees of large trials investigating the impact of new and old drugs, including digoxin(co-PI), iron therapy, sacubitril-valsartan, selenium/coQ10(PI), SGLT2i and potassium binders.
- He is a consultant cardiologist of the National Amyloidosis Center Groningen.
- He is full professor in cardiology and staff cardiologist, member of the LVAD and Heart Transplantation Team and currently chair of the department experimental cardiology of the University Medical Center Groningen.

**SELECTED PUBLICATIONS**

1. Hoes MF,.., **Van der Meer P.** Human iPSC-derived cardiomyocytes of peripartum cardiomyopathy patients reveal aberrant regulation of lipid metabolism. *Circulation* 2020;142:2288–2291.
2. Vermeer MC,.. , **Van der Meer P.** Gain-of-function mutation in KLHL24 causes desmin degradation and dilatation in hiPSC- derived engineered heart tissues.. *J Clin Invest.* 2021;131(17):e140615.
3. Grote Beverborg N, ....**Van der Meer P.** Phospholamban antisense oligonucleotides improve cardiac function in murine

cardiomyopathy. *Nat Commun.* 2021;12(1):5180.

4. Ponikowski P, ..., **van der Meer P**, ... Ferric carboxymaltose for iron deficiency at discharge after acute heart failure. *Lancet.* 2020:S0140-6736(20)32339-4.
5. Pfeffer M, ... **Van der Meer P**, ... Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. *N Engl J Med* 2021;385:1845-1855
6. Garcia, ... **Van der Meer P**, ... Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. *N Engl J Med.* 2023.
7. Tromp J, ... **Van der Meer P**. Novel endotypes in HF: effects on guideline-directed medical therapy. *Eur Heart J* 2018;39:4269–4276.
8. Ter Maaten JM, Beldhuis IE, **van der Meer P et al.** Natriuresis-guided diuretic therapy in acute HF: a pragmatic randomized trial. *Nat Med.* 2023
9. Kosiborod MN, ... **Van der Meer P**, ... Semaglutide in Patients with HFpEF and Obesity. *N Engl J Med.* 2023
10. Markousis-Mavrogenis, ... **Van der Meer P**. Immunomodulation and immunopharmacology in heart failure. *Nat Rev Cardiol.* 2024;119-149

### **Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society**

*150 words maximum*

- Van der Meer was a member of the 2016 ESC HF guidelines writing committee and reviewer of the updated 2023 HF guidelines.
- He was voted by his peers as treasurer (2020-2022) and secretary (2022-2024) of the ESC Council of Cardio-Oncology.
- He was member of the writing committee of the 2022 ESC guidelines on Cardio-Oncology.
- Since 2012 he is member of the working group PeriPartumCardiomyopathy (PPCM) which has the goal to better understand this devastating disease in young women.
- He was a member of the writing committee of the 2022 ESC guidelines on non-cardiac surgery.
- Since 2017 he is a member of the board of the Dutch Heart Failure Society.
- Since 2022 he is a non-voting member (sui generis) of the HFA board and member of the working groups translational cardiology and amyloidosis of the HFA. He participated in the development and drafting of several HFA position papers.

### **Why are you motivated to join the HFA Board or Nominating Committee?**

*150 words maximum*

The care for patients suffering from heart failure is and has been my driving force. It is my sincere belief that, through solid research, better education and improving organization, we can increase life expectancy and quality of life of our patients. An HFA board membership would allow me to extend my involvement in the heart failure community, and I look forward improving education and research, through HFA meetings and research networks. As a clinical cardiologist with a strong focus on translational science I'm very motivated to bolster the translational research within the HFA. I believe that a strong collaboration between basic and clinical researchers will lead to better treatment and ultimately improve outcome. Furthermore, as member of the board of the Dutch Heart Failure Association, I will serve as a liaison for the Dutch heart failure community on ESC's behalf.

### **How will you combine your HFA position with your daily clinical/research workload?**

*80 words maximum*

As a cardiologist working at a University Medical Center, I spend 40% of my time in the clinics, 20% of my time on management tasks (chair of the department of experimental cardiology). The rest of my time I focus on research and within these 40% I would have sufficient time to combine this with an HFA board position.

